Natural killer-22 cells in the synovial fluid of patients with rheumatoid arthritis are an innate source of interleukin 22 and tumor necrosis factor-α

Journal of Rheumatology

Volumn 38, Issue 10, 2011, Pages 2112-2118

  Ren, Jie ^a   Feng, Zhitao ^a   Lv, Zhuo ^a   Chen, Xiaoguang ^a   Li, Juan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Flow cytometry; Interleukin 22; Natural killer 22 cells; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

CHEMOKINE RECEPTOR CCR6; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 22; MONOCYTE CHEMOTACTIC PROTEIN 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; NATURAL KILLER 22 CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIOCYTE;

ADULT; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; CHEMOKINE CCL2; FEMALE; HUMANS; INTERLEUKINS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80053510030     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.101377     Document Type: Article

References (19)

1. Gay S, Gay RE, Koopman WJ. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? Ann Rheum Dis 1993;52 Suppl 1:S39-47. (Pubitemid 23094332)
2. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 1997;186:1677-87. (Pubitemid 27506281)
3. Nilsson N, Bremell T, Tarkowski A, Carlsten H. Protective role of NK1.1+ cells in experimental Staphylococcus aureus arthritis. Clin Exp Immunol 1999;117:63-9. (Pubitemid 29292779)
4. French AR, Yokoyama WM. Natural killer cells and autoimmunity. Arthritis Res Ther 2004;6:8-14. (Pubitemid 38256082)
5. Moretta L, Biassoni R, Bottino C, Cantoni C, Pende D, Mingari MC, et al. Human NK cells and their receptors. Microbes Infect 2002;4:1539-44. (Pubitemid 36050823)
6. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001;97:3146-51.
7. Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004;173:6418-26. (Pubitemid 39487802)
8. De Matos CT, Berg L, Michaelsson J, Fellander-Tsai L, Karre K, Soderstrom K. Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunology 2007;122:291-301. (Pubitemid 47389957)
9. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009;457:722-5.
10. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-51. (Pubitemid 46232884)
11. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005;52:1037-46. (Pubitemid 40530109)
12. Grunebaum E, Malatzky-Goshen E, Shoenfeld Y. Natural killer cells and autoimmunity. Immunol Res 1989;8:292-304. (Pubitemid 19277877)
13. Pridgeon C, Lennon GP, Pazmany L, Thompson RN, Christmas SE, Moots RJ. Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright, CD94bright, CD158negative phenotype. Rheumatology 2003;42:870-8. (Pubitemid 37220937)
14. Di Santo JP. Functionally distinct NK-cell subsets: developmental origins and biological implications. Eur J Immunol 2008;38:2948-51.
15. Krzysiek R, Lefevre EA, Bernard J, Foussat A, Galanaud P, Louache F, et al. Regulation of CCR6 chemokine receptor expression and responsiveness to macrophage inflammatory protein-3 alpha/CCL20 in human B cells. Blood 2000;96:2338-45.
16. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440. (Pubitemid 26130190)
17. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989;170:1627-33. (Pubitemid 19284562)
18. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7. (Pubitemid 19180612)
19. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992;90:772-9.